The use of radiation therapy to treat cancer is well known. Typically, radiation therapy involves directing a beam of high energy proton, photon, ion, or electron radiation (“therapeutic radiation”) into a target or target volume (e.g., a tumor or lesion).
Before a patient is treated with radiation, a treatment plan specific to that patient is developed. The plan defines various aspects of the therapy using simulations and optimizations based on past experiences. In general, the purpose of the treatment plan is to deliver sufficient radiation to the target while minimizing exposure of surrounding normal, healthy tissue to the radiation.
The planner's goal is to find a solution that is optimal with respect to multiple clinical goals that may be contradictory in the sense that an improvement toward one goal may have a detrimental effect on reaching another goal. For example, a treatment plan that spares the liver from receiving a dose of radiation may result in the stomach receiving too much radiation. These types of tradeoffs lead to an iterative process in which the planner creates different plans to find the one plan that is best suited to achieving the desired outcome.
A recent radiobiology study has demonstrated the effectiveness of delivering an entire, relatively high therapeutic radiation dose to a target within a single, short period of time. This type of treatment is referred to generally herein as FLASH radiation therapy (FLASH RT). Evidence to date suggests that FLASH RT advantageously spares normal, healthy tissue from damage when that tissue is exposed to only a single irradiation for only a very short period of time. FLASH RT thus introduces important constraints that are not considered in or achieved with conventional radiation treatment planning.
In intensity modulated radiation therapy (IMRT) such as intensity modulated particle therapy (IMPT), beam intensity is varied across each treatment region (target) in a patient. Depending on the treatment modality, the degrees of freedom available for intensity modulation include beam shaping (collimation), beam weighting (spot scanning), and angle of incidence (which may be referred to as beam geometry). These degrees of freedom lead to effectively an infinite number of potential treatment plans, and therefore consistently and efficiently generating and evaluating high-quality treatment plans is beyond the capability of a human and relies on the use of a computing system, particularly considering the time constraints associated with the use of radiation therapy to treat ailments like cancer, as well as the large number of patients that are undergoing or need to undergo radiation therapy during any given time period.
Embodiments according to the present invention provide an improved method of radiation treatment planning, and improved radiation treatment based on such planning, for FLASH radiation therapy (FLASH RT). In embodiments, a prescribed dose to be delivered into and uniformly across the target is determined. Directions (e.g., gantry angles relative to the patient or target, or nozzle directions relative to the patient or target) for delivering beams into the target are determined. This can include determining the number of beams (the number of directions from which beams are to be delivered). The directions are determined such that the beams do not overlap outside the target; that is, to take advantage of the normal tissue sparing effect of FLASH RT, each sub-volume of normal (healthy) tissue is irradiated only once. The beams can overlap inside the target. The beams' paths can lie within the same plane, or they can be in different planes. An energy for each of the beams is also determined. The number of beams, the directions of the beams, and beam energies are determined such that the calculated or predicted cumulative doses inside the target satisfy the prescribed dose across the target. An iterative process can be used to determine the number of beams, the directions of the beams, and beam energies.
In embodiments, a beam energy is determined for each of the directions (for each of the beams). The beam energy for each direction is determined such that calculated cumulative doses across the target (at locations inside the target where the beams' paths overlap) satisfy the prescribed dose. In embodiments, a beam includes a number of beam segments or beamlets. In one or more such embodiments, a maximum energy for the beam is specified, and an energy for each of the beam segments is determined as a percentage (100 percent or less) or equivalent fraction of the maximum beam energy. In general, beams can have the same energy or different energies, and each beam can have a range of energies. Thus, different energies can be delivered in different directions, and different energies can be delivered in each direction.
Embodiments according to the invention improve radiation treatment planning and the treatment itself by expanding FLASH RT to a wider variety of treatment platforms and target sites (e.g., tumors). Treatment plans generated as described herein are superior for sparing normal tissue from radiation in comparison to conventional techniques for FLASH dose rates and even non-FLASH dose rates by reducing, if not minimizing, the magnitude of the dose, and in some cases the integrated dose, to normal tissue (outside the target) by design. When used with FLASH dose rates, management of patient motion is simplified. Treatment planning, while still a complex task, is simplified relative to conventional planning.
In summary, embodiments according to this disclosure pertain to generating and implementing a treatment plan that is the most effective (relative to other plans) and with the least (or most acceptable) side effects (e.g., the lowest dose outside of the region being treated). Thus, embodiments according to the invention improve the field of radiation treatment planning specifically and the field of radiation therapy in general. Embodiments according to the invention allow more effective treatment plans to be generated quickly. Also, embodiments according to the invention help improve the functioning of computer systems because, for example, by reducing the complexity of generating treatment plans, fewer computational resources are needed and consumed to develop the plans, meaning also that computer resources are freed up to perform other tasks.
In addition to IMRT and IMPT, embodiments according to the invention can be used in spatially fractionated radiation therapy including high-dose spatially fractionated grid radiation therapy and microbeam radiation therapy.
These and other objects and advantages of embodiments according to the present invention will be recognized by one skilled in the art after having read the following detailed description, which are illustrated in the various drawing figures.
This summary is provided to introduce a selection of concepts in a simplified form that is further described below in the detailed description that follows. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
The accompanying drawings, which are incorporated in and form a part of this specification and in which like numerals depict like elements, illustrate embodiments of the present disclosure and, together with the detailed description, serve to explain the principles of the disclosure.
Reference will now be made in detail to the various embodiments of the present disclosure, examples of which are illustrated in the accompanying drawings. While described in conjunction with these embodiments, it will be understood that they are not intended to limit the disclosure to these embodiments. On the contrary, the disclosure is intended to cover alternatives, modifications and equivalents, which may be included within the spirit and scope of the disclosure as defined by the appended claims. Furthermore, in the following detailed description of the present disclosure, numerous specific details are set forth in order to provide a thorough understanding of the present disclosure. However, it will be understood that the present disclosure may be practiced without these specific details. In other instances, well-known methods, procedures, components, and circuits have not been described in detail so as not to unnecessarily obscure aspects of the present disclosure.
Some portions of the detailed descriptions that follow are presented in terms of procedures, logic blocks, processing, and other symbolic representations of operations on data bits within a computer memory. These descriptions and representations are the means used by those skilled in the data processing arts to most effectively convey the substance of their work to others skilled in the art. In the present application, a procedure, logic block, process, or the like, is conceived to be a self-consistent sequence of steps or instructions leading to a desired result. The steps are those utilizing physical manipulations of physical quantities. Usually, although not necessarily, these quantities take the form of electrical or magnetic signals capable of being stored, transferred, combined, compared, and otherwise manipulated in a computing system. It has proven convenient at times, principally for reasons of common usage, to refer to these signals as transactions, bits, values, elements, symbols, characters, samples, pixels, or the like.
It should be borne in mind, however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities. Unless specifically stated otherwise as apparent from the following discussions, it is appreciated that throughout the present disclosure, discussions utilizing terms such as “determining,” “accessing,” “directing,” “controlling,” “defining,” “arranging,” “generating,” or the like, refer to actions and processes (e.g., the flowcharts of
Portions of the detailed description that follows are presented and discussed in terms of a method. Although steps and sequencing thereof are disclosed in figures herein (e.g.,
Embodiments described herein may be discussed in the general context of computer-executable instructions residing on some form of computer-readable storage medium, such as program modules, executed by one or more computers or other devices. By way of example, and not limitation, computer-readable storage media may comprise non-transitory computer storage media and communication media. Generally, program modules include routines, programs, objects, components, data structures, etc., that perform particular tasks or implement particular abstract data types. The functionality of the program modules may be combined or distributed as desired in various embodiments.
Computer storage media includes volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer-readable instructions, data structures, program modules or other data. Computer storage media includes, but is not limited to, random access memory (RAM), read only memory (ROM), electrically erasable programmable ROM (EEPROM), flash memory or other memory technology, compact disk ROM (CD-ROM), digital versatile disks (DVDs) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium that can be used to store the desired information and that can accessed to retrieve that information.
Communication media can embody computer-executable instructions, data structures, and program modules, and includes any information delivery media. By way of example, and not limitation, communication media includes wired media such as a wired network or direct-wired connection, and wireless media such as acoustic, radio frequency (RF), infrared and other wireless media. Combinations of any of the above can also be included within the scope of computer-readable media.
The system 100 also includes input device(s) 124 such as keyboard, mouse, pen, voice input device, touch input device, etc. Output device(s) 126 such as a display device, speakers, printer, etc., are also included.
In the example of
In the example of
The treatment planning tool set 310 searches through the knowledge base 302 (through the patient records 304) for prior patient records that are similar to the current patient record 312. The statistical models 308 can be used to compare the predicted results for the current patient record 312 to a statistical patient. Using the current patient record 312, a selected treatment type 306, and selected statistical models 308, the tool set 310 generates a radiation treatment plan 322.
More specifically, based on past clinical experience, when a patient presents with a particular diagnosis, stage, age, weight, sex, co-morbidities, etc., there can be a treatment type that is used most often. By selecting the treatment type that the planner has used in the past for similar patients, a first-step treatment type 314 can be chosen. The medical image processing module 316 provides automatic contouring and automatic segmentation of two-dimensional cross-sectional slides (e.g., from computed tomography or magnetic resonance imaging) to form a three-dimensional (3D) image using the medical images in the current patient record 312. Dose distribution maps are calculated by the dose distribution module 320, which may utilize the optimizer model 150.
In embodiments according to the present invention, the optimizer model 150 uses a dose prediction model to help shape the dose distribution. The optimizer model 150 can provide, for example, a 3D dose distribution, fluences, and associated dose-volume histograms for the current patient.
The beam system 404 generates and transports a beam 401 to the nozzle 406. In general, the beam 401 can be a proton beam, electron beam, photon beam, ion beam, or atom nuclei beam (e.g., carbon, helium, and lithium). In embodiments, the beam 401 is a proton beam. In another embodiment, the beam 401 is an ion beam.
In embodiments, depending on the type of beam, the beam system 404 includes components that direct (e.g., bend, steer, or guide) the beam through the system in a direction toward and into the nozzle 406. In embodiments, the radiation therapy system 400 may also include one or more multileaf collimators (MLCs); each MLC leaf can be independently moved back-and-forth by the control system 410 to dynamically shape an aperture through which the beam can pass, to block or not block portions of the beam and thereby control beam shape and exposure time. The beam system 404 may also include components that are used to adjust (e.g., reduce) the beam energy entering the nozzle 406.
The nozzle 406 may be mounted on or a part of a gantry (
The nozzle 406 is used to aim the beam toward various locations (a target) within an object (e.g., a patient) supported on the patient support device 408 in a treatment room. In embodiments, the patient support device 408 is a table or couch that supports the patient in a supine position. In another embodiment, the patient support device 408 is a chair in which the patient sits. A chair can offer some advantages relative to a couch or table. Some patients are uncomfortable in a supine position or find it difficult to stay in that position. A chair can be moved more easily than a couch. A chair can have more degrees of freedom relative to a couch. In other words, by using a chair, it may be possible to more comfortably change the position of the patient relative to the nozzle 406 in more ways than are possible using a couch. As such, use of a chair to move the patient relative to the nozzle 406 may reduce the number of times the heavier gantry needs to be moved or eliminate the need to move the gantry at all. If the gantry does not need to be moved, then the nozzle 406 can remain stationary, pointing in a single direction with the beam directed only towards one wall of the treatment room. Consequently, thicker shielding would be needed only for that one wall, reducing costs and also reducing the overall room footprint. The magnitude of motion for an upright position in a chair is also smaller than lying down on a couch. This is favorable for high-precision treatments. In addition, absolute lung volumes are larger in the upright position, which can reduce mean lung dose. A chair also provides larger solid angle coverage, no collisions, and real time tracking.
A target may be an organ, a portion of an organ (e.g., a volume or region within the organ), a tumor, diseased tissue, or a patient outline.
The control system 410 of
As noted above, the beam entering the nozzle 406 has a specified energy. Thus, in embodiments according to the present disclosure, the nozzle 406 includes one or more components that affect (e.g., decrease, modulate) the energy of the beam. The term “beam energy adjuster” is used herein as a general term for a component or components that affect the energy of the particles in the beam, in order to control the range of the beam (e.g., the extent that the beam penetrates into a target), to control the dose delivered by the beam, and/or to control the depth dose curve of the beam, depending on the type of beam. For example, for a proton beam or an ion beam that has a Bragg peak, the beam energy adjuster can control the location of the Bragg peak in the target. In various embodiments, the beam energy adjuster 407 includes a range modulator, a range shifter, or both a range modulator and a range shifter. That is, when the term “beam energy adjuster” is used, then the element being discussed may be a range modulator, a range shifter, or both a range modulator and a range shifter. Examples of a beam energy adjuster for proton beams and ion beams are disclosed in the co-pending patent application, U.S. application Ser. No. 15/089,330, now U.S. Pat. No. 9,855,445, entitled “Radiation Therapy Systems and Methods for Delivering Doses to a Target Volume;” however, the invention is not so limited.
In intensity modulated radiation therapy (IMRT) such as intensity modulated particle therapy (IMPT), beam intensity is varied across each treatment region (target) in a patient. Depending on the treatment modality, the degrees of freedom available for intensity modulation include beam shaping (collimation), beam weighting (spot scanning), and angle of incidence (which may be referred to as beam geometry). These degrees of freedom lead to effectively an infinite number of potential treatment plans, and therefore consistently and efficiently generating and evaluating high-quality treatment plans is beyond the capability of a human and relies on the use of a computing system, particularly considering the time constraints associated with the use of radiation therapy to treat ailments like cancer, as well as the large number of patients that are undergoing or need to undergo radiation therapy during any given time period.
In block 502 of
In block 504, directions (e.g., gantry angles relative to the patient or target, or nozzle directions relative to the patient or target) for delivering beams into the target are determined or accessed from a memory of a computing system. The operation of determining or accessing beam directions also includes determining or accessing the number of beams (the number of directions from which beams are to be delivered). In general, when generating the radiation treatment plan, one goal is to determine beam paths that minimize the irradiation time of each sub-volume or voxel of the tissue outside the target. Ideally, each sub-volume or voxel outside the target is intersected, at most, by only a single beam. That is, ideally, the beams' paths do not overlap outside the target. If some overlap between beam paths is permitted, then ideally each sub-volume or voxel outside the target is intersected by not more than two beams, with most intersected by only a single beam. In embodiments, as one means of achieving the aforementioned goal, the directions are determined such that the total amount of overlap between the beams' paths is minimized outside the target. In another such embodiment, the directions are determined so that the paths of the beams do not overlap at all outside the target. The beams' paths can overlap within the target. The beams' paths can lie within the same plane, or they can be in different planes. Additional information is provided in conjunction with
Any number of other factors may be considered when determining the beam directions. These factors may include the shape and size (e.g., height H and width W, or diameter) of the beam in the beam's eye view (see
In block 506 of
While the operations in blocks 502, 504, and 506 of
Once a final set of values for number of beams, their directions, and their energies are determined, then those values (as well as other values for other parameters known in the art) can be stored as a radiation treatment plan in the memory of a computer system, from which it can be subsequently accessed.
Although multiple beams are shown in
In the examples of
As will be discussed further in conjunction with
The dose delivered to each portion of the target 604 is cumulative, based on the number of beams that are delivered to and through that portion. For example, the portions of the target 604 covered by the beams 605 and 607 receive a total dose that is the sum of the dose delivered by the beam 605 and the dose delivered by the beam 607. In embodiments, the energies of the beams (beam segments) are accurately determined so that, even though the dose along each beam (or beam segment) is not uniform, a uniform cumulative dose distribution is achieved within and across the target 604.
For implementations that use proton beams or ion beams, the dose delivered by each beam at the respective proximal portion (or edge) of the target 604 may be different from (e.g., less than) the dose delivered by that beam at the respective distal portion (or edge) of the target (as before, proximal and distal are with reference to the source of the beam).
The dose delivered to each portion of the target 604 is cumulative, based on the number of beams that are delivered to and through that portion. Not all beams are depicted in the figures for simplicity; in general, the number of beams is sufficient to achieve a uniform cumulative dose distribution within the target 604.
In general, the surface of a target can be viewed as having a number of discrete facets. From this perspective, for beams other than photon beams, each incident beam is orthogonal to each facet such that the beams do not overlap outside the target. In the case of photon beams, each incident beam is parallel to the facet and does not overlap other beams outside the target.
In the
Each beam segment can deliver a relatively high dose in a relatively short period of time. For example, each beam segment can deliver at least 4 Gy in less than one second, and may deliver as much as 20 Gy or 50 Gy or more in less than one second. The energy or intensity of each beam segment can be controlled using the beam energy adjuster 407 of
In operation, in embodiments, the beam segments are delivered sequentially. For example, the beam segment 704 is delivered to the target (turned on) and then turned off, then the beam segment 706 is turned on then off, then the beam segment 708 is turned on then off, and so on. Each beam segment may be turned on for only a fraction of a second (on the order of milliseconds).
With reference back to
In block 802 of
In block 804, the beams are directed into the target according to the treatment plan, thereby delivering the prescribed dose uniformly across the target.
In the present embodiments, system requirements are illustrated by the following example. To deliver 20 Gy at a rate of 40 Gy/sec, the gantry should rotate though 180 degrees in less than 0.5 seconds (60 RPM). Assuming a five millimeter slice and an MLC modulation factor of three, required gantry and MLC leaf speeds on can be achieved using conventional radiotherapy devices. Technologies relevant to high speed MLCs include pneumatic or electromagnetic drives.
Compared to the
In the embodiments of
In summary, embodiments according to the invention improve radiation treatment planning and the treatment itself by expanding FLASH RT to a wider variety of treatment platforms and target sites. Treatment plans generated as described herein are superior for sparing normal tissue from radiation in comparison to conventional techniques even for non-FLASH dose rates by reducing, if not minimizing, the magnitude (and the integral in some cases) of the dose to normal tissue (outside the target) by design. When used with FLASH dose rates, management of patient motion is simplified. Treatment planning, while still a complex task of finding a balance between competing and related parameters, is simplified relative to conventional planning. The techniques described herein may be useful for stereotactic radiosurgery as well as stereotactic body radiotherapy with single or multiple metastases.
In addition to IMRT and IMPT, embodiments according to the invention can be used in spatially fractionated radiation therapy including high-dose spatially fractionated grid radiation therapy and microbeam radiation therapy.
Although the subject matter has been described in language specific to structural features and/or methodological acts, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described above. Rather, the specific features and acts described above are disclosed as example forms of implementing the claims.
This application is a continuation application of U.S. application Ser. No. 15/657,052, now U.S. Pat. No. 10,549,117, by R. Vanderstraeten et al., entitled “Geometric Aspects of Radiation Therapy Planning and Treatment,” filed Jul. 21, 2017, and hereby incorporated by reference in its entirety, which was related to U.S. application Ser. No. 15/657,094, now U.S. Pat. No. 10,092,774, by R. Vanderstraeten et al., entitled “Dose Aspects of Radiation Therapy Planning and Treatment,” filed Jul. 21, 2017, also hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4163901 | Azam | Aug 1979 | A |
4914681 | Klingenbeck et al. | Apr 1990 | A |
5153900 | Nomikos et al. | Oct 1992 | A |
5267294 | Kuroda | Nov 1993 | A |
5550378 | Skillicorn et al. | Aug 1996 | A |
5610967 | Moorman et al. | Mar 1997 | A |
5625663 | Swerdloff et al. | Apr 1997 | A |
5682412 | Skillicorn et al. | Oct 1997 | A |
5757885 | Yao et al. | May 1998 | A |
6198802 | Elliott et al. | Mar 2001 | B1 |
6222544 | Tarr et al. | Apr 2001 | B1 |
6234671 | Solomon et al. | May 2001 | B1 |
6260005 | Yang et al. | Jul 2001 | B1 |
6379380 | Satz | Apr 2002 | B1 |
6411675 | Llacer | Jun 2002 | B1 |
6445766 | Whitham | Sep 2002 | B1 |
6504899 | Pugachev et al. | Jan 2003 | B2 |
6580084 | Hiramoto et al. | Jun 2003 | B1 |
6580940 | Gutman | Jun 2003 | B2 |
6888832 | Richardson et al. | May 2005 | B2 |
6993112 | Hesse | Jan 2006 | B2 |
7268358 | Ma et al. | Sep 2007 | B2 |
7423278 | Amaldi et al. | Sep 2008 | B2 |
7453983 | Schildkraut et al. | Nov 2008 | B2 |
7515681 | Ebstein | Apr 2009 | B2 |
7522706 | Lu et al. | Apr 2009 | B2 |
7554275 | Amaldi | Jun 2009 | B2 |
7560715 | Pedroni | Jul 2009 | B2 |
7590219 | Maurer, Jr. et al. | Sep 2009 | B2 |
7616735 | Maciunas et al. | Nov 2009 | B2 |
7623623 | Raanes et al. | Nov 2009 | B2 |
7778691 | Zhang et al. | Aug 2010 | B2 |
7807982 | Nishiuchi et al. | Oct 2010 | B2 |
7831289 | Riker et al. | Nov 2010 | B2 |
7835492 | Sahadevan | Nov 2010 | B1 |
7907699 | Long et al. | Mar 2011 | B2 |
8071966 | Kaiser et al. | Dec 2011 | B2 |
8121253 | Nelms | Feb 2012 | B2 |
8253121 | Gnutzmann et al. | Aug 2012 | B2 |
8284898 | Ho et al. | Oct 2012 | B2 |
8306184 | Chang et al. | Nov 2012 | B2 |
8401148 | Lu et al. | Mar 2013 | B2 |
8405056 | Amaldi et al. | Mar 2013 | B2 |
8406844 | Ruchala et al. | Mar 2013 | B2 |
8559596 | Thomson et al. | Oct 2013 | B2 |
8600003 | Zhou et al. | Dec 2013 | B2 |
8613694 | Walsh | Dec 2013 | B2 |
8618521 | Loo et al. | Dec 2013 | B2 |
8636636 | Shukla et al. | Jan 2014 | B2 |
8644571 | Schulte | Feb 2014 | B1 |
8699664 | Otto et al. | Apr 2014 | B2 |
8716663 | Brusasco et al. | May 2014 | B2 |
8798343 | Kabus et al. | Aug 2014 | B2 |
8836332 | Shvartsman et al. | Sep 2014 | B2 |
8847179 | Fujitaka et al. | Sep 2014 | B2 |
8901519 | Schardt et al. | Dec 2014 | B2 |
8903471 | Heid | Dec 2014 | B2 |
8917813 | Maurer, Jr. | Dec 2014 | B2 |
8948341 | Beckman | Feb 2015 | B2 |
8958864 | Amies et al. | Feb 2015 | B2 |
8983573 | Carlone et al. | Mar 2015 | B2 |
8986186 | Zhang et al. | Mar 2015 | B2 |
8992404 | Graf et al. | Mar 2015 | B2 |
8995608 | Zhou et al. | Mar 2015 | B2 |
9018603 | Loo et al. | Apr 2015 | B2 |
9033859 | Fieres et al. | May 2015 | B2 |
9079027 | Agano et al. | Jul 2015 | B2 |
9149656 | Tanabe | Oct 2015 | B2 |
9155908 | Meltsner et al. | Oct 2015 | B2 |
9233260 | Slatkin et al. | Jan 2016 | B2 |
9258876 | Cheung et al. | Feb 2016 | B2 |
9283406 | Prieels | Mar 2016 | B2 |
9308391 | Liu et al. | Apr 2016 | B2 |
9330879 | Lewellen et al. | May 2016 | B2 |
9333374 | Iwata | May 2016 | B2 |
9468777 | Fallone et al. | Oct 2016 | B2 |
9517358 | Velthuis et al. | Dec 2016 | B2 |
9526918 | Kruip | Dec 2016 | B2 |
9545444 | Strober et al. | Jan 2017 | B2 |
9583302 | Figueroa Saavedra et al. | Feb 2017 | B2 |
9636381 | Basile | May 2017 | B2 |
9636525 | Sahadevan | May 2017 | B1 |
9649298 | Djonov et al. | May 2017 | B2 |
9656098 | Goer | May 2017 | B2 |
9694204 | Hardemark | Jul 2017 | B2 |
9776017 | Flynn et al. | Oct 2017 | B2 |
9786054 | Taguchi et al. | Oct 2017 | B2 |
9786093 | Svensson | Oct 2017 | B2 |
9786465 | Li et al. | Oct 2017 | B2 |
9795806 | Matsuzaki et al. | Oct 2017 | B2 |
9801594 | Boyd et al. | Oct 2017 | B2 |
9844358 | Wiggers et al. | Dec 2017 | B2 |
9854662 | Mishin | Dec 2017 | B2 |
9884206 | Schulte et al. | Feb 2018 | B2 |
9931522 | Bharadwaj et al. | Apr 2018 | B2 |
9962562 | Fahrig et al. | May 2018 | B2 |
9974977 | Lachaine et al. | May 2018 | B2 |
9987502 | Gattiker et al. | Jun 2018 | B1 |
10007961 | Grudzinski et al. | Jun 2018 | B2 |
10022564 | Thieme et al. | Jul 2018 | B2 |
10071264 | Liger | Sep 2018 | B2 |
10080912 | Kwak et al. | Sep 2018 | B2 |
10092774 | Vanderstraten et al. | Oct 2018 | B1 |
10183179 | Smith et al. | Jan 2019 | B1 |
10188875 | Kwak et al. | Jan 2019 | B2 |
10206871 | Lin et al. | Feb 2019 | B2 |
10212800 | Agustsson et al. | Feb 2019 | B2 |
10232193 | Iseki | Mar 2019 | B2 |
10258810 | Zwart et al. | Apr 2019 | B2 |
10272264 | Ollila et al. | Apr 2019 | B2 |
10279196 | West et al. | May 2019 | B2 |
10293184 | Pishdad et al. | May 2019 | B2 |
10307614 | Schnarr | Jun 2019 | B2 |
10307615 | Ollila et al. | Jun 2019 | B2 |
10315047 | Glimelius et al. | Jun 2019 | B2 |
10413755 | Sahadevan | Sep 2019 | B1 |
10449389 | Ollila et al. | Oct 2019 | B2 |
10485988 | Kuusela et al. | Nov 2019 | B2 |
10525285 | Friedman | Jan 2020 | B1 |
10549117 | Vanderstraten et al. | Feb 2020 | B2 |
10603514 | Grittani et al. | Mar 2020 | B2 |
10609806 | Roecken et al. | Mar 2020 | B2 |
10636609 | Bertsche et al. | Apr 2020 | B1 |
10660588 | Boyd et al. | May 2020 | B2 |
10661100 | Shen | May 2020 | B2 |
10682528 | Ansorge et al. | Jun 2020 | B2 |
10702716 | Heese | Jul 2020 | B2 |
10758746 | Kwak et al. | Sep 2020 | B2 |
10870018 | Bartkoski et al. | Dec 2020 | B2 |
20060274061 | Wang et al. | Dec 2006 | A1 |
20070034812 | Ma et al. | Feb 2007 | A1 |
20070287878 | Fantini et al. | Dec 2007 | A1 |
20080023644 | Pedroni | Jan 2008 | A1 |
20080049897 | Molloy | Feb 2008 | A1 |
20080226030 | Otto | Sep 2008 | A1 |
20090063110 | Failla et al. | Mar 2009 | A1 |
20090287467 | Sparks et al. | Nov 2009 | A1 |
20100119032 | Fan et al. | May 2010 | A1 |
20100177870 | Nord et al. | Jul 2010 | A1 |
20100178245 | Arnsdorf et al. | Jul 2010 | A1 |
20100260317 | Chang et al. | Oct 2010 | A1 |
20110006214 | Bonig | Jan 2011 | A1 |
20110006224 | Maltz et al. | Jan 2011 | A1 |
20110091015 | Yu et al. | Apr 2011 | A1 |
20110135058 | Sgouros et al. | Jun 2011 | A1 |
20120076271 | Yan et al. | Mar 2012 | A1 |
20120136194 | Zhang et al. | May 2012 | A1 |
20120157746 | Meltsner et al. | Jun 2012 | A1 |
20120171745 | Itoh | Jul 2012 | A1 |
20120197058 | Shukla et al. | Aug 2012 | A1 |
20130116929 | Carlton et al. | May 2013 | A1 |
20130150922 | Butson et al. | Jun 2013 | A1 |
20130177641 | Ghoroghchian | Jul 2013 | A1 |
20130231516 | Loo et al. | Sep 2013 | A1 |
20140177807 | Lewellen et al. | Jun 2014 | A1 |
20140185776 | Li et al. | Jul 2014 | A1 |
20140206926 | van der Laarse | Jul 2014 | A1 |
20140275706 | Dean et al. | Sep 2014 | A1 |
20140369476 | Harding | Dec 2014 | A1 |
20150011817 | Feng | Jan 2015 | A1 |
20150057484 | Amaldi | Feb 2015 | A1 |
20150202464 | Brand et al. | Jul 2015 | A1 |
20150306423 | Bharat et al. | Oct 2015 | A1 |
20160193482 | Fahrig et al. | Jul 2016 | A1 |
20160279444 | Schlosser | Sep 2016 | A1 |
20160310764 | Bharadwaj et al. | Oct 2016 | A1 |
20170028220 | Schulte et al. | Feb 2017 | A1 |
20170189721 | Sumanaweera et al. | Jul 2017 | A1 |
20170203129 | Dessy | Jul 2017 | A1 |
20170281973 | Allen et al. | Oct 2017 | A1 |
20180021594 | Papp et al. | Jan 2018 | A1 |
20180043183 | Sheng et al. | Feb 2018 | A1 |
20180056090 | Jordan et al. | Mar 2018 | A1 |
20180099154 | Prieels | Apr 2018 | A1 |
20180099155 | Prieels et al. | Apr 2018 | A1 |
20180099159 | Forton et al. | Apr 2018 | A1 |
20180154183 | Sahadevan | Jun 2018 | A1 |
20180197303 | Jordan et al. | Jul 2018 | A1 |
20180207425 | Carlton et al. | Jul 2018 | A1 |
20180236268 | Zwart et al. | Aug 2018 | A1 |
20190022407 | Abel et al. | Jan 2019 | A1 |
20190022422 | Trail et al. | Jan 2019 | A1 |
20190054315 | Isola et al. | Feb 2019 | A1 |
20190070435 | Joe Anto et al. | Mar 2019 | A1 |
20190168027 | Smith et al. | Jun 2019 | A1 |
20190255361 | Mansfield | Aug 2019 | A1 |
20190299027 | Fujii et al. | Oct 2019 | A1 |
20190299029 | Inoue | Oct 2019 | A1 |
20190351259 | Lee et al. | Nov 2019 | A1 |
20200001118 | Snider, III et al. | Jan 2020 | A1 |
20200022248 | Yi et al. | Jan 2020 | A1 |
20200030633 | Van Heteren et al. | Jan 2020 | A1 |
20200035438 | Star-Lack et al. | Jan 2020 | A1 |
20200069818 | Jaskula-Ranga et al. | Mar 2020 | A1 |
20200164224 | Vanderstraten et al. | May 2020 | A1 |
20200178890 | Otto | Jun 2020 | A1 |
20200197730 | Safavi-Naeini et al. | Jun 2020 | A1 |
20200254279 | Ohishi | Aug 2020 | A1 |
20200269068 | Abel et al. | Aug 2020 | A1 |
20200276456 | Swerdloff | Sep 2020 | A1 |
20200282234 | Folkerts et al. | Sep 2020 | A1 |
Number | Date | Country |
---|---|---|
104001270 | Aug 2014 | CN |
106687177 | May 2017 | CN |
106730407 | May 2017 | CN |
107362464 | Nov 2017 | CN |
109966662 | Jul 2019 | CN |
111481840 | Aug 2020 | CN |
111481841 | Aug 2020 | CN |
010207 | Jun 2008 | EA |
0979656 | Feb 2000 | EP |
3043863 | Jul 2016 | EP |
3103519 | Dec 2016 | EP |
3338858 | Jun 2018 | EP |
3384961 | Oct 2018 | EP |
3421087 | Jan 2019 | EP |
3453427 | Mar 2019 | EP |
3586920 | Jan 2020 | EP |
2617283 | Jun 1997 | JP |
2014161706 | Sep 2014 | JP |
2017098000 | Jun 2017 | JP |
2019097969 | Jun 2019 | JP |
2007017177 | Feb 2007 | WO |
2010018476 | Feb 2010 | WO |
2013081218 | Jun 2013 | WO |
2013133936 | Sep 2013 | WO |
2014139493 | Sep 2014 | WO |
2015038832 | Mar 2015 | WO |
2015102680 | Jul 2015 | WO |
2016122957 | Aug 2016 | WO |
2017156316 | Sep 2017 | WO |
2017174643 | Oct 2017 | WO |
2018137772 | Aug 2018 | WO |
2018152302 | Aug 2018 | WO |
2019097250 | May 2019 | WO |
2019103983 | May 2019 | WO |
2019164835 | Aug 2019 | WO |
2019166702 | Sep 2019 | WO |
2019185378 | Oct 2019 | WO |
2019222436 | Nov 2019 | WO |
2020018904 | Jan 2020 | WO |
2020064832 | Apr 2020 | WO |
2020107121 | Jun 2020 | WO |
2020159360 | Aug 2020 | WO |
Entry |
---|
Wen C. His, Michael F. Moyers, Dmitri Nichporov, Vladimir Anferov, Mark Wolanski, Chris E. Allgower, Jonathan B. Farr, Anthony E. Mascia, Andreis N. Schreuder, “Energy spectrum control for modulated proton beams”, Medical Physics, (2009) 36(6) 2297-2308, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832068/. |
V. Anferov, M. Ball, G.P. Berg, B. Broderick, J. Collins, G. East, D. Friesel, D. Jenner, W.P. Jones, J. Katuin, S. Klein, C. Nelson, N. Schreuder, Wm. Starks, J. Self, “The Indiana University Midwest Proton Radiation Institute”, Proceedings of the 2001 Particle Accelerator Conference, (2001) p. 645-647 https://accelconf.web.cem.ch/accelconf/301/PAPERS/FOAA004.PDF. |
Th. Haberer, W. Beecher,D. Schardt,G. Kraft “Magnetic scanning system for heavy ion therapy” Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, NIM, Elsevie, Jun. 10, 1993, vol. 330, Issues 1-2, Jun. 10, 1993, pp. 296-305. Amaldi, TERA Foundation, Novara, Italy A. Degiovanni, CERN, Geneva, Switzerland Linac 2014. Proton and Carbon Linacs for Hadron Therapy U. http://accelconf.web.cern.ch/AccelConf/LINAC2014/papers/friob02.pdf. pp. 1207-1212. |
Montay-Gruel P, Petersson K, Jaccard M, Boivin G, Germond JF, Petit B, Doenlen R, Favaudon V, Bochud F, Bailat C, Bourhis J, Vozenin MC. Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with dose rates above 100Gy/s. Radiother Oncol. May 22, 2017. pii: S0167-8140(17)30365-1. doi: 10.1016/j.radonc.2017.05.003. [Epub ahead of print] PubMed PMID: 28545957. |
Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, Poupon MF, Brito I, Hupe P, Bourhis J, Hall J, Fontaine JJ, Vozenin MC. Ultrahigh dose-rate Flash irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. Jul. 16, 2014;6(245):245ra93. doi: 10.1126/scitranslmed.3008973. PubMed PMID: 25031268. |
Loo BW, Schuler E, Lartey FM, Rafat M, King GJ, Trovati S, Koong AC, Maxim PG. Delivery of Ultra-Rapid Flash Radiation Therapy and Demonstration of Normal Tissue Sparing After Abdominal Irradiation of Mice. International Journal of Radiation Oncology Biology Physics, vol. 98 Issue: 2 p. E16-E16 Supplement: S Meeting Abstract: P003 Published: Jun. 1, 2017. |
K. Peach, et al. “PAMELA—A Model for an FFAG Based Hadron Therapy Machine”, Proceedings of PAC07, Albuquerque, New Mexico, USA. pp. 2880-2882. S. Benedetti, A. Grudiev, and A. Latina Phys. Rev. Accel. Beams 20, 040101—Published Apr. 13, 2017. |
Valery Dolgashev, Sami Tantawi, Yasuo Higashi, Bruno Spataro, “Geometric dependence of radio-frequency breakdown in normal conducting accelerating structures,” Applied Physics Letters, vol. 97, Issue 17, pp. 171501-171501-3, Oct. 2010. American Institute of Physics. |
Lisa Laurent, Sami Tantawi, Valery Dolgashev, Chris Nantista, Yasuo Higashi, Markus Aicheler, Samuli Heikkinen, and Walter Wuensch, Experimental Study of RF Pulsed Heating Phys. Rev. ST Accel. Beams 14, 041001 (2011) [21 pages]. |
S. Tantawi, Z. Li , et al. patent pending, Title: “Distributed Coupling and Multi-Frequency Microwave Accelerators”, Filed: Jul. 9, 2014, U.S. Appl. No. 62/022,469. |
S. Tantawi, M.Nasar, “Designs and High Power Tests of Distributed Coupling Linacs” IFIC, Jun. 13-16, 2017, Valencia, Spainhttps://indico.cem.ch.event589548/contributions/2615455/attachments-/1479738/2294080/Mamdough_High_Gradient_2017.pdf. |
Jensen, Aaron, Jeff Neilson, and Sami Tantawi. “X-band multi-beam klystron design and progress report.” Vacuum Electronics Conference (IVEC), 2015 IEEE International. IEEE, 2015. |
K.Halbach, “Design of permanent multipole magnets with oriented rare earth cobalt material”, Nuclear Instruments and Methods , vol. 169, Issue 1, Feb. 1, 1980, pp. 1-12 [http://www.sciencedirect.com/science/article/oii/0029554X80900944]. |
J. K. Lim, P. Frigola, G. Travish, J. B. Rosenzweig, S. G. Anderson, W. J. Brown, J. S. Jacob, C. L. Robbins, and A. M. Tremaine, “An Adjustable, short focal length permanent-magnet quadrupole based electron beam final focus system” Phys. Rev. ST Accel. Beams 8, 072401—Published Jul. 15, 2005. 19 pages, Sayyed Bijan Jiaa, Mohammad Hadi Hadizadeha, Ali Asghar Mowlavi ,Mandy Ebrahimi Loushab “Evaluation of energy deposition and secondary particle production in proton therapy of brain using a slab head phantom” Elsevier, Reports. |
J.Perl, J Shin, J Schumann, B Faddegon and H Paganetti, “TOPAS—An innovative proton Monte Carlo platform for research and clinical applications,” Med. Phys. 39:6818-6837, 2012, PMID: 23127075, PMID: 23127075. |
Lisa Polster, Jan Schuemann, Ilaria Rinaldi, Lucas Burigo, Aimee Louise McNamara, Robert D Stewart, Andrea Attili, David J. Carlson, Alejandro Carabe-Fernadez, Bruce Faddegon, Joseph Perl, and Harald Paganetti, “Extension of TOPAS for the simulation of proton radiation on molecular and cellular endpoints,” Phys Med Biol. Jun. 10, 2015;60 (13):5053-5070, PMID: 26061583. |
Qiyong Fan, Akshay Nanduri, Samuel Mazin, Lei Zhu, “Emission guided radiation therapy for lung and prostate cancers: A feasibility study on a digital patient”, Med. Phys. 39 (11), Nov. 2012, 0094-2405/2012/39(11)/7140/13, 13 pages. |
Valerie Devillaine, Radiotherapy and radiation biology, Radiotherapy—new treatment methods, Radio-toxicity, radio resistance and pediatric cancers, Photo-sensitization and retinoblastoma, 6 pages. Radiotherapy “flashes” to reduce side effects, An effect for each mode of adminisIralion, Images of tissue sections, Ultra-high dose-rate, Science Translational Medicine, Jul. 16, 2014, 3 pages. |
To introduce the concept of pseudo beam's-eye-view (pBEV), to establish a framework for computer-assisted beam orientation selection in intensity-modulated radiation therapy(IMRT), and to evaluate the utility of the proposed techniquie, Dec. 1, 2001 vol 51, Issue 5, 3 pages, Pseudo beam's-eye-view as applied to beam orientation selection in intensity-modulated radiation therapy. |
Aafke Christine Kraan, “Range verification methods in particle therapy: underlying physics and Monte Carlo modeling,” Frontiers in Oncology, Jul. 7, 2015, vol. 5, Article 150, 27 pages, doi: 10.3389/fonc.2015.00150. |
Wayne D. Newhauser et al., “The physics of proton therapy,” Physics in Medicine & Biology, Mar. 24, 2015, 60 R155-R209, Institute of Physics and Engineering in Medicine, IOP Publishing, doi: 10.1088/0031-9155/60/8/R155. |
S E McGowan et al., “Treatment planning optimisation in proton therapy,” Br J Radiol, 2013, 86, 20120288, The British Institute of Radiology, 12 pages, DOI: 10.1259 bjr.20120288. |
Steven Van De Water et al., “Towards FLASH proton therapy: the impact of treatment planning and machine characteristics on achievable dose rates,” Acta Oncologica, Jun. 26, 2019, vol. 58, No. 10, p. 1462-1469, Taylor & Francis Group, DOI: 10.1080/0284186X.2019.1627416. |
J. Groen, “Flash optimisation in clinical IMPT treatment planning,” MSc Thesis, Jul. 1, 2020, Erasmus University Medical Center, department of radiotherapy, Delft University of Technology, 72 pages. |
Muhammad Ramish Ashraf et al., “Dosimetry for FLASH Radiotherapy: A Review of Tools and the Role of Radioluminescence and Cherenkov Emission,” Frontiers in Oncology, Aug. 21, 2020, vol. 8, Article 328, 20 pages, doi: 10.3389/fphy.2020.00328. |
Emil Schuler et al., “Experimental Platform for Ultra-high Dose Rate FLASH Irradiation of Small Animals Using a Clinical Linear Accelerator,” International Journal of Radiation Oncology, Biology, Physics, vol. 97, No. 1, Sep. 2016, op. 195-203. |
Elette Engels et al., “Toward personalized synchrotron microbeam radiation therapy,” Scientific Reports, 10:8833, Jun. 1, 2020, 13 pages, DOI: https://doi.org/10.1038/s41598-020-65729-z. |
P-H Mackeprang et al., “Assessing dose rate distributions in VMAT plans” (Accepted Version), Accepted Version: https://boris.unibe.ch/92814/8/dose_rate_project_revised_submit.pdf Published Version: 2016, Physics in medicine and biology, 61(8), pp. 3208-3221. Institute of Physics Publishing IOP, published Mar. 29, 2016, https://boris.unibe.ch/92814/. |
Xiaoying Liang et al., “Using Robust Optimization for Skin Flashing in Intensity Modulated Radiation Therapy for Breast Cancer Treatment: A Feasibility Study,” Practical Radiation Oncology, vol. 10, Issue 1, p. 59-69, Published by Elsevier Inc., Oct. 15, 2019. |
Alexei Trofimov et al., “Optimization of Beam Parameters and Treatment Planning for Intensity Modulated Proton Therapy,” Technology in Cancer Research & Treatment, vol. 2, No. 5, Oct. 2003, p. 437-444, Adenine Press. |
Vladimir Anferov, “Scan pattern optimization for uniform proton beam scanning,” Medical Physics, vol. 36, Issue 8, Aug. 2009, pp. 3560-3567, First published: Jul. 2, 2009. |
Ryosuke Kohno et al., “Development of Continuous Line Scanning System Prototype for Proton Beam Therapy,” International Journal of Particle Therapy, Jul. 11, 2017, vol. 3, Issue 4, p. 429-438, DOI: 10.14338/IJPT-16-00017.1. |
Wenbo Gu et al., “Integrated Beam Orientation and Scanning-Spot Optimization in Intensity Modulated Proton Therapy for Brain and Unilateral Head and Neck Tumors,” Med Phys. Author manuscript; available in PMC Apr. 1, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904040/Published in final edited form as: Med Phys. Apr. 2018; 45(4): 1338-1350. Published online Mar. 1, 2018. doi: 10 1002/mp.12788 Accepted manuscript online: Feb. 2, 2018. |
Paul Morel et al., “Spot weight adaptation for moving target in spot scanning proton therapy,” Frontiers in Oncology, May 28, 2015, vol. 5, Article 119, 7 pages, doi: 10.3389/fonc.2015.00119. |
Simeon Nill et al., “Inverse planning of intensity modulated proton therapy,” Zeitschrift fur Medizinische Physik, vol. 14, Issue 1, 2004, pp. 35-40, https://doi.org/10.1078/0939-3889-00198. |
A. Lomax, “Intensity modulation methods for proton radiotherapy,” Physics in Medicine & Biology, Jan. 1999, vol. 14, No. 1, pp. 185-205, doi: 10.1088/0031-9155/44/1/014. |
M Kramer et al., “Treatment planning for heavy-ion radiotherapy: physical beam model and dose optimization,” Physics in Medicine & Biology, 2000, vol. 45, No. 11, pp. 3299-3317, doi: 10.1088/0031-9155/45/11/313. |
Harald Paganetti, “Proton Beam Therapy,” Jan. 2017, Physics World Discovery, IOP Publishing Ltd, Bristol, UK, 34 pages, DOI: 10.1088/978-0-7503-1370-4. |
Shinichi Shimizu et al., “A Proton Beam Therapy System Dedicated to Spot-Scanning Increases Accuracy with Moving Tumors by Real-Time Imaging and Gating and Reduces Equipment Size,” PLoS ONE, Apr. 18, 2014, vol. 9, Issue 4, e94971, https://doi.org/10.1371/journal.pone.0094971. |
Heng Li et al., “Reducing Dose Uncertainty for Spot-Scanning Proton Beam Therapy of Moving Tumors by Optimizing the Spot Delivery Sequence,” International Journal of Radiation Oncology, Biology, Physics, vol. 93, Issue 3, Nov. 1, 2015, pp. 547-556, available online Jun. 18, 2015, https://doi.org/10.1016/j.ijrobp.2015.06.019. |
Ion Beam Applications SA, “Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation,” Imaging Technology News, May 2, 2019, Wainscot Media, https://www.itnonline.com/content/netherlands-proton-therapy-center-delivers-first-clinical-flash-irradiation. |
R. M. De Kruijff, “Flash radiotherapy: ultra-high dose rates to spare healthy tissue,” International Journal of Radiation Biology, 2020, vol. 96, No. 4, pp. 419-423, published online: Dec. 19, 2019, https://doi.org/10.1080/09553002.2020.1704912. |
Mevion Medical Systems, “Focus On The Future: Flash Therapy,” Press Releases, Sep. 16, 2019, https://www.mevion.com/newsroom/press-releases/focus-future-flash-therapy. |
Joseph D. Wilson et al., “Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?”, Frontiers in Oncology, Jan. 17, 2020, vol. 9, Article 1563, 12 pages, doi: 10.3389/fonc. 2019.01563. |
David P. Gierga, “Is Flash Radiotherapy coming?”, International Organization for Medical Physics, 2020, https://www.iomp.org/iomp-news2-flash-radiotherapy/. |
Abdullah Muhammad Zakaria et al., “Ultra-High Dose-Rate, Pulsed (FLASH) Radiotherapy with Carbon Ions: Generation of Early, Transient, Highly Oxygenated Conditions in the Tumor Environment,” Radiation Research, Dec. 1, 2020, vol. 194, Issue 6, pp. 587-593, Radiation Research Society, Published: Aug. 27, 2020, doi: https://doi.org/10.1667/RADE-19-00015.1. |
Yusuke Demizu et al., “Carbon Ion Therapy for Early-Stage Non-Small-Cell Lung Cancer,” BioMed Research International, vol. 2014, Article ID 727962, 9 pages, Hindawi Publishing Corporation, published: Sep. 11, 2014, https://doi.org/10.1155/2014/727962. |
Vana Dokic et al., “Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams,” Oncotarget, Aug. 30, 2016, vol. 7, No. 35, pp. 56676-56689, published online: Aug. 1, 2016, doi: 10.18632/oncotarget.10996. |
Aetna Inc., “Proton Beam, Neutron Beam, and Carbon Ion Radiotherapy,” 2020, No. 0270, http://www.aetna.com/cpb/medical/data/200_299/0270.html. |
Nicholas W. Colangelo et al., “The Importance and Clinical Implications of FLASH Ultra-High Dose-Rate Studies or Proton and Heavy Ion Radiotherapy,” Radiat Res. Author manuscript; available in PMC Jan. 1, 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949397/ Published in final edited form as: Radiat Res. Jan. 2020; 193(1): 1-4. Published online Oct. 28, 2019. doi: 10.1667/RR15537.1. |
Vincent Favaudon et al., “Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice,” Science Translational Medicine, Jul. 16, 2014, vol. 6, Issue 245, 245ra93, American Association for the Advancement of Science, DOI: 10.1126/scitranslmed.3008973. |
“FlashRad: Ultra-high dose-rate FLASH radiotherapy to minimize the complications of radiotherapy,” 2014, https://siric.curie.fr/sites/default/files/atoms/files/flashrad.pdf. |
Tami Freeman, “Flash radiotherapy: from preclinical promise to the first human treatment,” Physics World, Aug. 6, 2019, IOP Publishing Ltd, https://physicsworld.com/a/flash-radiotherapy-from-preclinical-promise-to-the-first-human-treatment/. |
Intraop Medical, Inc., “IntraOp and Lausanne University Hospital Announce Collaboration in FLASH adiotherapy,” Jun. 18, 2020, https://intraop.com/news-events/lausanne-university-flash-radiotherapy-collaboration/. |
M.-C. Vozenin et al., “Biological Benefits of Ultra-high Dose Rate FLASH Radiotherapy: Sleeping Beauty Awoken,” Clin Oncol (R Coll Radiol). Author manuscript; available in PMC Nov. 12, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850216/Published in final edited form as: Clin Oncol (R Coll Radiol). Jul. 2019; 31(7): 407-415. Published online Apr. 19, 2019. doi: 10.1016/j.clon.2019 04.001. |
Efstathios Kamperis et al., “A Flash back to radiotherapy's past and then fast forward to the future,” J Cancer Prev Curr Res. 2019;10(6):142-144. published Nov. 13, 2019, DOI: 10.15406/jcpcr.2019.10.00407. |
P. Symonds et al., “FLASH Radiotherapy: The Next Technological Advance in Radiation Therapy?”, Clinical Oncology, vol. 31, Issue 7, p. 405-406, Jul. 1, 2019, The Royal College of Radiologists, Published by Elsevier Ltd., DOI: https://doi.org/10.1016/j.clon.2019.05.011. |
Swati Girdhani et al., “Abstract LB-280: Flash: A novel paradigm changing tumor irradiation platform that enhances therapeutic ratio by reducing normal tissue toxicity and activating immune pathways,” Proceedings: AACR Annual Meeting 2019; Mar. 29-Apr. 3, 2019; Atlanta, GA, published Jul. 2019, vol. 79, Issue 13 Supplement, pp. LB-280, American Association for Cancer Research, DOI: https://doi.org/10.1158/1538-7445.AM2019-LB-280. |
Bazalova-Carter et al., “On the capabilities of conventional x-ray tubes to deliver ultra-high (FLASH) dose rates,” Med. Phys. Dec. 2019; 46 (12):5690-5695, published Oct. 23, 2019, American Association of Physicists in Medicine, doi: 10.1002/mp. 13858. Epub Oct. 23, 2019. PMID: 31600830. |
Manuela Buonanno et al., “Biological effects in normal cells exposed to FLASH dose rate protons,” Radiother Oncol. Author manuscript; available in PMC Oct. 1, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728238/Published in final edited form as: Radiother Oncol. Oct. 2019; 139: 51-55. Published online Mar. 5, 2019. doi: 10.1016/j.radonc.2019.02 009. |
N. Rama et al., “Improved Tumor Control Through T-cell Infiltration Modulated by Ultra-High Dose Rate Proton FLASH Using a Clinical Pencil Beam Scanning Proton System,” International Journal of Radiation Oncology, Biology, Physics, vol. 105, Issue 1, Supplement , S164-S165, Sep. 1, 2019, Mini Oral Sessions, DOI: https://doi.org/10.1016/j.ijrobp.2019.06.187. |
INSERM PRESS OFFICE, “Radiotherapy ‘flashes’ to reduce side effects,” Press Release, Jul. 16, 2014, https://presse.inserm.fr/en/radiotherapy-flashes-to-reduce-side-effects/13394/. |
Eric S. Diffenderfer et al., “Design, Implementation, and in Vivo Validation of a Novel Proton FLASH Radiation Therapy System,” International Journal of Radiation Oncology, Biology, Physics, vol. 106, Issue 2, Feb. 1, 2020, pp. 440-448, Available online Jan. 9, 2020, Published by Elsevier Inc., DOI: https://doi.org/10.1016/j.ijrobp.2019.10.049. |
Valerie Devillaine, “Radiotherapy and Radiation Biology,” Institut Curie, Apr. 21, 2017, https://institut-curie.org/page/radiotherapy-and-radiation-biology. |
Imaging Technology News, “ProNova and medPhoton to Offer Next Generation Beam Delivery, Advanced Imaging for Proton Therapy,” Oct. 6, 2014, Wainscot Media, Link: https://www.itnonline.com/content/pronova-and-medphoton-offer-next-generation-beam-delivery-advanced-imaging-proton-therapy. |
Oncolink Team, “Radiation Therapy: Which type is right for me?”, OncoLink Penn Medicine, last reviewed Mar. 3, 2020, Trustees of the University of Pennsylvania, https://www.oncolink.org/cancer-treatment/radiation/introduction-to-radiation-therapy/radiation-therapy-which-type-is-right-for-me. |
Marco Durante et al., “Faster and safer? FLASH ultra-high dose rate in radiotherapy,” Br J Radiol 2018; 91(1082): 20170628, British Institute of Radiology, Published Online: Dec. 15, 2017, https://doi.org/10.1259/bjr.20170628. |
John R. Fischer, “PMB launches FLASH radiotherapy system for use in clinical trials,” Healthcare Business News, Jun. 29, 2020, DOTmed.com, Inc., https://www.dotmed.com/news/story/51662. |
Marie-Catherine Vozenin et al., “The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients,” Clinical Cancer Research, Author Manuscript Published OnlineFirst Jun. 6, 2018, https://clincancerres.aacrjournals.org/content/clincanres/early/2018/06/06/1078-0432.CCR-17-3375.full.pdf. |
M. McManus et al., “The challenge of ionisation chamber dosimetry in ultra-short pulsed high dose-rate Very High Energy Electron beams,” Sci Rep 10, 9089 (2020), published Jun. 3, 2020, https://doi.org/10.1038/S41598-020-65819-y. |
Ibrahim Oraiqat et al., “An Ionizing Radiation Acoustic Imaging (iRAI) Technique for Real-Time Dosimetric Measurements for FLASH Radiotherapy,” Medical Physics, vol. 47, Issue10, Oct. 2020, pp. 5090-5101, First published: Jun. 27, 2020, https://doi.org/10.1002/mp.14358. |
K. Petersson et al., “Dosimetry of ultra high dose rate irradiation for studies on the biological effect induced in normal brain and GBM,” ICTR-PHE 2016, p. S84, Feb. 2016, https://publisher-connector.core.ac.uk/resourcesync/data/elsevier/pdf/14c/aHR0cDovL2FwaS5lbHNIdmllci5jb20vY29udGVudC9hcnRpY2xIL3BpaS9zMDE2NzgxNDAxNjMwMTcyNA==.pdf. |
Susanne Auer et al., “Survival of tumor cells after proton irradiation with ultra-high dose rates,” Radiation Oncology 2011, 6:139, Published Oct. 18, 2011, DOI: https://doi.org/10.1186/1748-717X-6-139. |
Cynthia E. Keen, “Clinical linear accelerator delivers FLASH radiotherapy,” Physics World, Apr. 23, 2019, IOP Publishing Ltd, https://physicsworld.com/a/clinical-linear-accelerator-delivers-flash-radiotherapy/. |
Fan et al., “Emission guided radiation therapy for lung and prostate cancers: A feasibility study on a digital patient,” Med Phys. Nov. 2012; 39(11): 7140-7152. Published online Nov. 5, 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505203/doi: 10.1118/1.4761951. |
Favaudon et al., “Ultrahigh dose-rate, “flash” irradiation minimizes the side-effects of radiotherapy,” Cancer/Radiotherapy, vol. 19, Issues 6-7 , Oct. 2015 , pp. 526-531, Available online Aug. 12, 2015, https://doi.org/10.1016/j.canrad.2015.04.006. |
O. Zlobinskaya et al., “The Effects of Ultra-High Dose Rate Proton Irradiation on Growth Delay in the Treatment of Human Tumor Xenografts in Nude Mice,” Radiation Research, 181(2):177-183. Published Feb. 13, 2014, DOI: http://dx.doi.org/10.1667/RR13464.1. |
Bjorn Zackrisson, “Biological Effects of High Energy Radiation and Ultra High Dose Rates,” UMEA University Medical Dissertations, New series No. 315-ISSN 0346-6612, From the Department of Oncology, University of Umea, Umea, Sweden, ISBN 91-7174-614-5, Printed in Sweden by the Printing Office of Umea University, Umea, 1991. |
P. Montay-Gruel et al., “Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with dose rates above 100 Gy/s,” Radiotherapy and Oncology, vol. 124, Issue 3, Sep. 2017, pp. 365-369, Available online May 22, 2017, doi: 10.1016/j.radonc.2017.05.003. |
BW Loo et al., “Delivery of Ultra-Rapid Flash Radiation Therapy and Demonstration of Normal Tissue Sparing After Abdominal Irradiation of Mice,” International Journal of Radiation Oncology, Biology, Physics, vol. 98, Issue 2, p. E16, Supplements Meeting Abstract: P003, Published: Jun. 1, 2017, DOI: https://doi.org/10.1016/j.ijrobp.2017.02.101. |
Bhana Prasad Venkatesulu et al., “Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome,” Sci Rep 9, 17180 (2019), Published Nov. 20, 2019, DOI: https://doi.org/10.1038/s41598-019-53562-y. |
P. Montay-Gruel et al., “Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species,” PNAS May 28, 2019, vol. 116, No. 22, pp. 10943-10951; first published May 16, 2019, https://doi.org/10.1073/pnas.1901777116. |
Peter G. Maxim et al., “FLASH radiotherapy: Newsflash or flash in the pan?”, Medical Physics, 46 (10), Oct. 2019, pp. 4287-4290, American Association of Physicists in Medicine, First published: Jun. 27, 2019, https://doi.org/10.1002/mp.13685. |
Andrei Pugachev et al., “Pseudo beam's-eye-view as applied to beam orientation selection in intensity-modulated radiation therapy,” Int. J. Radiation Oncology Biol. Phys., vol. 51, Issue 5, p. 1361-1370, Dec. 1, 2001, DOI: https://doi.org/10.1016/S0360-3016(01)01736-9. |
Xiaodong Zhang et al., “Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared With Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical Study,” Int. J. Radiation Oncology Biol. Phys., Vol. 77, No. 2, pp. 357-366, 2010, Available online Aug. 5, 2009, DOI: https://doi.org/10.1016/j.ijrobp.2009.04.028. |
A. J. Lomax et al., “Intensity modulated proton therapy: A clinical example,” Medical Physics, vol. 28, Issue 3, Mar. 2001, pp. 317-324, First published: Mar. 9, 2001, https://doi.org/10.1118/1.1350587. |
Lamberto Widesott et al., “Intensity-Modulated Proton Therapy Versus Helical Tomotherapy in Nasopharynx Cancer: Planning Comparison and NTCP Evaluation,” Int. J. Radiation Oncology Biol. Phys., vol. 72, No. 2, pp. 589-596, Oct. 1, 2008, Available online Sep. 13, 2008, DOI: https://doi.org/10.1016/j.ijrobp.2008.05.065. |
Andrei Pugachev et al., “Role of beam orientation optimization in intensity-modulated radiation therapy,” Int. J. Radiation Oncology Biol. Phys., vol. 50, No. 2, pp. 551-560, Jun. 1, 2001, Available online May 10, 2001, DOI: https://doi.org/10.1016/S0360-3016(01 )01502-4. |
Damien C. Weber et al., “Radiation therapy planning with photons and protons for eady and advanced breast cancer: an overview,” Radiat Oncol. 2006; 1: 22. Published online Jul. 20, 2006, doi: 10.1186/1748-717X-1-22. |
RaySearch Laboratories, “Leading the way in cancer treatment, Annual Report 2013,” RaySearch Laboratories (publ), Stockholm, Sweden, 94 pages, Apr. 2014, https://www.raysearchlabscom/siteassets/about-overview/media-center/wp-re-ev-n-pdfs/brochures/raysearch-ar-2013-eng-pdf. |
Fredrik Carlsson, “Utilizing Problem Structure in Optimization of Radiation Therapy,” KTH Engineering Sciences, Doctoral Thesis, Stockholm, Sweden, Apr. 2008, Optimization and Systems Theory, Department of Mathematics, Royal Institute of Technology, Stockholm, Sweden, ISSN 1401-2294, https://www. raysearchlabs.com/globalassets/about-overview/media-center/wp-re-ev-n-pdfs/publications/thesis-fredrik_light.pdf. |
Chang-Ming Charlie Ma, “Physics and Dosimetric Principles of SRS and SBRT,” Mathews J Cancer Sci. 4(2): 22, 2019, published: Dec. 11, 2019, ISSN: 2474-6797, DOI: https://doi.org/10.30654/MJCS.10022. |
Alterego-admin, “Conventional Radiation Therapy May Not Protect Healthy Brain Cells,” International Neuropsychiatric Association-INA, Oct. 10, 2019, https://inawebsite.org/conventional-radiation-therapy-may-not-protect-healthy-brain-cells/. |
Number | Date | Country | |
---|---|---|---|
20200164224 A1 | May 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15657052 | Jul 2017 | US |
Child | 16778857 | US |